Tumor necrosis factor-related apoptosis-inducing ligand in vascular inflammation and atherosclerosis: a protector or culprit? (Q38275877)

1 September 2017

1 reference

title

Tumor necrosis factor-related apoptosis-inducing ligand in vascular inflammation and atherosclerosis: a protector or culprit? (English)

1 reference

1 September 2017

0 references

1 reference

Wen Cheng

1

1 reference

1 September 2017

Yuxia Zhao

series ordinal

2

1 reference

1 September 2017

Shuangxi Wang

series ordinal

3

1 reference

1 September 2017

Fan Jiang

series ordinal

4

1 reference

1 September 2017

publication date

5 November 2014

1 reference

1 September 2017

published in

Vascular Pharmacology

1 reference

1 September 2017

volume

63

1 reference

1 September 2017

issue

3

1 reference

1 September 2017

page(s)

135-144

1 reference

TRAIL receptor signaling and therapeutics.

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Natural regulatory T cells control the development of atherosclerosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms of PDGF-BB-mediated VSMC proliferation and migration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL: not just for tumors anymore?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Human mast cells undergo TRAIL-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL mediated signaling in human mast cells: the influence of IgE-dependent activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Potential role of TRAIL in the management of autoimmune diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

State of art and recent developments of anti-cancer strategies based on TRAIL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Perivascular Mast Cells Promote Atherogenesis and Induce Plaque Destabilization in Apolipoprotein E–Deficient Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Association of soluble Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) with central adiposity and low-density lipoprotein cholesterol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Phenotypical and functional specialization of FOXP3+ regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Involvement of caspase 8 and c-FLIPL in the proangiogenic effects of the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Loss of perivascular adipose tissue on peroxisome proliferator-activated receptor-γ deletion in smooth muscle cells impairs intravascular thermoregulation and enhances atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Apoptotic phenotype alters the capacity of tumor necrosis factor-related apoptosis-inducing ligand to induce human vascular endothelial activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Lipopolysaccharide-induced expression of TRAIL promotes dendritic cell differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL-induced apoptosis: between tumor therapy and immunopathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Association of soluble tumour necrosis factor-related apoptosis-inducing ligand levels with coronary plaque burden and composition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Role of smooth muscle cells in the initiation and early progression of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Hyperlipidemia-Triggered Neutrophilia Promotes Early Atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Phosphatidylinositol 3-kinase is required for insulin-like growth factor-I-induced vascular smooth muscle cell proliferation and migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Following TRAIL's path in the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Life and death by death receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Inflammation, atherosclerosis, and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Innate and adaptive immunity in the pathogenesis of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Activated mast cells induce endothelial cell apoptosis by a combined action of chymase and tumor necrosis factor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

JNK/SAPK activity contributes to TRAIL-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Scavenger receptors for oxidized and glycated proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Dual Effects of TRAIL in Suppression of Autoimmunity: The Inhibition of Th1 Cells and the Promotion of Regulatory T Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Dissociation of apoptosis induction and CD36 upregulation by enzymatically modified low-density lipoprotein in monocytic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Mast cell infiltration in acute coronary syndromes: implications for plaque rupture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Systemic delivery of TNF-related apoptosis-inducing ligand (TRAIL) elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobese diabetic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Expression, regulation and function of trail in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Following a TRAIL: update on a ligand and its five receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Up-regulation of TRAIL mRNA expression in peripheral blood mononuclear cells from patients with active systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Signaling through C/EBP homologous protein and death receptor 5 and calpain activation differentially regulate THP-1 cell maturation-dependent apoptosis induced by Shiga toxin type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Inflammation and immune system interactions in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL death receptor 4 signaling via lysosome fusion and membrane raft clustering in coronary arterial endothelial cells: evidence from ASM knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Inflammation in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Inflammation in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Inflammation in atherosclerosis: from pathophysiology to practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL/DR5 signaling promotes macrophage foam cell formation by modulating scavenger receptor expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

A novel receptor for Apo2L/TRAIL contains a truncated death domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Association of serum TRAIL level with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Innate and adaptive immunity in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Structural analyses of death domains and their interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Mechanisms that regulate macrophage burden in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Acceleration of human neutrophil apoptosis by TRAIL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Distinct infiltration of neutrophils in lesion shoulders in ApoE-/- mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Induction of TRAIL- and TNF-alpha-dependent apoptosis in human monocyte-derived dendritic cells by microfilariae of Brugia malayi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Mechanisms of disease: atherosclerosis in autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Mast cell deficiency attenuates progression of atherosclerosis and hepatic steatosis in apolipoprotein E-null mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL promotes caspase-dependent pro-inflammatory responses via PKCδ activation by vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Tissue distribution of the death ligand TRAIL and its receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Tumor necrosis factor-related apoptosis-inducing ligand promotes microvascular endothelial cell hyperpermeability through phosphatidylinositol 3-kinase pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Tumor necrosis factor-related, apoptosis-inducing ligand supports growth of mouse mastocytoma tumors by killing tumor-infiltrating macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL on trial: preclinical advances in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Scavenger receptors: friend or foe in atherosclerosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL and apoptosis induction by TNF-family death receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis by the expansion of CD4+CD25+ regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Mast cell chymase inhibits smooth muscle cell growth and collagen expression in vitro: transforming growth factor-beta1-dependent and -independent effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces chemotactic migration of monocytes via a death receptor 4-mediated RhoGTPase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Identification and characterization of a new member of the TNF family that induces apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Circulating level of TRAIL concentration is positively associated with endothelial function and increased by diabetic therapy in the newly diagnosed type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Preliminary clinical measurement of the expression of TNF-related apoptosis inducing ligand in patients with ankylosing spondylitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.10.004

10.1016/J.VPH.2014.10.004

7 January 2021

Identifiers

DOI

1 reference

1 September 2017

1 reference